Lung cancer drug dose doubled for stubborn tumors in new trial
NCT ID NCT07298148
First seen Jan 06, 2026 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests whether a higher dose (160 mg) of the targeted drug firmonertinib can shrink or control advanced EGFR-mutant lung cancer in people whose tumors stayed stable after 8 weeks on the standard 80 mg dose. About 28 adults with stage IV non-small cell lung cancer and no prior treatment will take the higher dose once daily. The goal is to see if the stronger dose improves response rates and delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.